4.2 Review

Sulfated glycosaminoglycans in protein aggregation diseases

期刊

GLYCOCONJUGATE JOURNAL
卷 34, 期 4, 页码 453-466

出版社

SPRINGER
DOI: 10.1007/s10719-017-9769-4

关键词

Protein aggregation disease; Amyloidosis; Glycosaminoglycan; Heparan sulfate

资金

  1. Japanese Health and Labour Sciences Research (Comprehensive Research on Aging and Health) [H22-007]
  2. Ministry of Education, Science, Sports, and Culture [24590349, 15 K08265, B-15 K19488]
  3. Takeda Science Foundation
  4. Kobayashi International Scholarship Foundation
  5. Grants-in-Aid for Scientific Research [24590349, 17K16123] Funding Source: KAKEN

向作者/读者索取更多资源

Protein aggregation diseases are characterized by intracellular or extracellular deposition of misfolded and aggregated proteins. These aggregated deposits contain multiple proteinaceous and non-protein components that are thought to play critical roles in the etiology and pathogenesis of protein aggregation diseases in vivo. One of these components, the sulfated glycosaminoglycans (GAGs), includes heparan sulfate, chondroitin sulfate, and keratan sulfate. The sulfated GAGs are negatively charged heteropolysaccharides expressed in all mammalian tissues. Enzymatically generated structural patterns and the degree of sulfation in GAGs determine GAGs' specific interactions with their protein ligands. Here, we review the potential roles of the sulfated GAGs in the pathogenesis and progression of protein aggregation diseases from a perspective of their sulfation modification. We also discuss the possibility of sulfated GAGs as therapeutic targets for protein aggregation diseases.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据